4
Tetrahedron Letters
The clay-supported Cu(II) catalyst was characterized using
benzaldehyde
(2a),
hydroxylamine
hydrochloride,
N-
XRD, SEM, TPR experiment and XPS analysis (see ESI).7 The
catalyst characterization results suggested that catalyst exists in
the form of highly dispersed CuO nanoparticles supported on
montmorillonite KSF (MKSF). The Cu content and total surface
area of the catalyst were found to be 8.83% and 96.4551 m2/g
respectively. Analysis of catalyst-sodium azide mixtures by XPS
evidenced the conversion of Cu(II) supported on clay to Cu(I)
state by treatment with sodium azide.7 This Cu(I) reacts with
acetylene to form copper(I) acetylide which undergoes stepwise
addition to in situ generated nitrile oxide furnishing 3,5-
disubstituted isoxazoles. The proposed mechanism for this
domino one-pot multicomponent protocol is depicted in Figure 3.
chlorosuccinamide, sodium azide and phenylacetylene (5a) in the
presence of clay-Cu(II)/NaN3 catalytic system led to formation of
isoxazole 1a in 84, 82, 82 and 80% over four cycles respectively.
In this recyclability study, catalyst was recovered by filtration
after each experiment. The SEM image of the used catalyst
showed similar morphology and the structural integrity after 4th
run, which clearly indicated that the Clay-Cu(II) catalyst is
robust, recyclable and was not affected under the reaction
conditions of this MCR protocol.
In summary, we have developed a simple and efficient one-pot
multicomponent protocol for regioselective synthesis of 3,5-
disubstituted isoxazoles directly from aldehydes in good yields.
As nitrile oxides are obtained directly from oximes, the isolation
and handling of potentially harmful and unstable hydroximoyl
chlorides is avoided. The clay-Cu(II) catalyst is ligand-free,
leaching-free, easy to prepare, easy to handle, environmentally
friendly and can be recycled several times without significant
loss of catalytic activity; thus it will be highly useful for
economical synthesis of 3,5-disubstituted isoxazoles.
O
N
O
O
N
N
Cl
Br
1a, 6 h, 84%
1b, 6 h, 76%
1c, 6 h, 72%
O
N
O
N
O
N
O
N
F
O2N
H3CO
F
1e, 6 h, 75%
1f, 7h, 68%
1d, 5h, 70%
F
O
N
O
O
N
F
Cl
Acknowledgements
AKP, BAD and RRY are thankful to CSIR for award of Research
Fellowships. Authors thank analytical department, IIIM for NMR
and MS analysis of our compounds.
Cl
Cl
F
1i, 6 h, 78%
1h, 6 h, 72%
1g, 5 h, 88%
O
N
O
Cl
N
O
N
Supplementary material
F
Cl
Br
O
1l, 6 h, 70%
1j, 6 h, 80%
Spectra of catalyst and all new compounds. Supplementary data
associated with this article can be found, in the online version at
1k 6 h, 82%
F
O
N
O
N
O
O
N
Cl
N
O
H3CO
O2N
F
References and notes
Cl
Br
1n, 6 h, 68%
1p,10 h, 55%
1o, 8 h, 70%
1m, 6 h, 82%
1. For various pharmacological activities of isoxazoles, see: (a)
Musad, E. A.; Mohamed, R.; Saeed, B. A.; Vishwanath, B. S.;
Rai, K. M. L. Bioorg. Med. Chem. Lett. 2011, 21, 3536-3540; (b)
Kumar, A.; Maurya, R. A.; Sharma, S.; Ahmad, P.; Singh, A. B.;
Tamrakar, A. K.; Srivastava, A. K. Bioorg. Med. Chem. 2009, 17
5285–5292; (c) Haddad, T.; Gershman, R.; Dilis, R.; Labaree,
D.; Hochberg, R. B.; Hanson, R. N. Bioorg. Med. Chem. Lett.
2012, 22, 5999-6003.
Figure 2. Isoxazoles synthesized using optimized protocol (reaction time and
yields are mentioned).
O
N
1a
2. For references on synthesis of various isoxazoles, see: (a)
Ueda, M.; Sato, A.; Ikeda, Y.; Miyoshi, T.; Naito, T.; Miyata, O.
Org. Lett. 2010, 12, 2594-2597; (b) Minakata, S.; Okumura, S.;
Nagamachi, T.; Takeda, Y. Org. Lett. 2011, 13, 2966–2969; (c)
Praveen, C.; Kalyanasundaram, A.; Perumal, P. T. Synlett 2010,
777-781; (d) Tang, S.; He, J.; Sun, Y.; He, L.; She, X. Org. Lett.
2009, 11, 3982-3985; (e) Gayon, E.; Quinonero, O. e.; Lemouzy,
S.; Vrancken, E.; Campagne, J.-M. Org. Lett. 2011, 13, 6418–
6421; (f) Willy, B.; Rominger, F.; Müller, T. J. J. Synthesis 2008,
293-303; (g) Jackowski, O.; Lecourt, T.; Micouin, L. Org. Lett.
2011, 13, 5664-5667; (h) Waldo, J. P.; Larock, R. C. J. Org.
Chem. 2007, 72, 9643-9647; (i) Crossley, J. A.; Browne, D. L. J.
Org. Chem. 2010, 75, 5351-5354; (j) Sheng, S.-R.; Liu, X.-L.;
Xu, Q.; Song, C.-S. Synthesis 2003, 2763-2764; (k) Cecchi, L.;
Sarlo, F. D.; Machetti, F. Eur. J. Org. Chem. 2006, 4852-4860;
(l) Ahmed, M. S. M.; Kobayashi, K.; Mori, A. Org. Lett. 2005, 7,
4487-4489; (m) Bourbeau, M. P.; Rider, J. T. Org. Lett. 2006, 8,
3679-3680; (n) Chen, C.-Y.; Andreani, T.; Li, H. Org. Lett.
2011, 13, 6300-6303; (o) Stokes, B. J.; Vogel, C. V.; Urnezis, L.
K.; Pan, M.; Driver, T. G. Org. Lett. 2010, 12, 2884-2887.
NaN3
Clay Cu(II)
H
Clay Cu(I)
Clay Cu
5a
C
C
C
O
N
Clay Cu
C
C
C
Clay Cu
C
O
O
N
C
C
N
C
C
O
Clay Cu
C
N
OH
N
O
N
Cl
4a
3. For references on synthesis of 3,5-disubstituted isoxazoles,
see: (a) Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtsev, V. V.;
Noodleman, L.; Sharpless, K. B.; Fokin, V. V. J. Am. Chem. Soc.
2005, 127, 210-216; (b) Xu, J.; Hamme, A. T. Synlett 2008, 919-
923; (c) Hansen, T. V.; Wu, P.; Fokin, V. V. J. Org. Chem. 2005,
Figure 3. Plausible mechanism of one-pot multicomponent protocol for
synthesis of 3,5-disubstituted isoxazole 1a using clay-Cu(II)/NaN3 catalyst
The clay-Cu(II) catalyst was reused repeatedly to prove its
heterogeneous nature and its recyclability. The MCR between